Takeda Pharmaceutical Company Limited (TAK)
Takeda is a Japanese biopharmaceutical company with three core research areas, gastrointestinal and inflammation, neuroscience and oncology, plus plasma-derived therapies and a vaccine business. It has a presence in approximately 80 countries and regions, manufacturing sites around the world and major research centres in Japan and the United States, and the filing states that commercially it has a very significant presence in the United States, Japan and Europe as well as a growing business in China. The financial year ends in March and figures are stated in yen.
Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2026 it reported revenue of JPY 4,506 billion ($29.9 billion at the year's average rate), down 1.7% on the year before. Its profit attributable to shareholders was JPY -152 billion, and diluted earnings per share JPY -96.75.
Takeda Pharmaceutical (TAK) in brief
Takeda Pharmaceutical (TAK) reported revenue of JPY 4.51 trillion for the year to 31 March 2026, down 1.7% on the year before.
Read more
Loss attributable to shareholders was JPY 152 billion and the diluted loss per share JPY 96.75. Revenue was JPY 4.58 trillion in the year to 31 March 2025, JPY 4.26 trillion in the year to 31 March 2024, JPY 4.03 trillion in the year to 31 March 2023 and JPY 3.57 trillion in the year to 31 March 2022. Profit attributable to shareholders in the same years was JPY 108 billion, JPY 144 billion, JPY 317 billion and JPY 230 billion. Revenue grew 7.1% a year, compounded, over the five years to the year to 31 March 2026. At the close of 10 November 2026 the market cap of Takeda Pharmaceutical was $66.1 billion.The share in the US
| Last close | $20.91 on 10 November 2026 |
| 52-week range | $13.71 (10 November 2025) to $21.21 (5 November 2026) |
| Over one year | up 52.5% |
| Market cap | $66.1 billion: 1,579,836,830 shares outstanding at 31 March 2026 (20-F, one ADS is half a share), each US share standing for 0.5 of an ordinary share |
US dollars per share as it trades in the US; the market cap and the P/E are worked out here, not filed. Prices from IEX, for splits.
Ratios
From the latest annual report, the year to Mar 2026, in dollars
ROE-2.1%
ROCE0.1%
Operating margin0.1%
Net margin-3.4%
FCF margin19.2%
Interest cover0.02
Debt to equity0.66
Cash conversionn/a
Share count, last 12 months-0.2%
Sales CAGR, 3 years3.8%
Profit CAGR, 3 yearsn/a
EPSn/a
At the close of 10 November 2026
Price$20.91
Market cap$66.1 billion
Stock P/En/a
Price to book1.41
EV / EBITDAn/a
Dividend yield3.1%
Market cap / sales2.32
52-week high$21.21
52-week low$13.71
Price, 1 year52.5%
Price CAGR, 3 yearsn/a
Price CAGR, 5 yearsn/a
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowings total Takeda Pharmaceutical Company Limited states in its annual report, never added up from its parts; lease liabilities are a separate line. Nothing here is a valuation or a view.TAKgreeksoup.ai
Daily prices to 10 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. This company reports once a year, so every view here moves once a year, on the day each annual report was filed, and holds until the next. P/E is the close over the year's EPS per US share: the EPS as filed, times the 0.5 of an ordinary share one US share stands for, in dollars at the year's average exchange rate (Federal Reserve, from FRED). Sales and margin are each year's revenue in dollars and its operating margin. EV/EBITDA, price to book and market cap to sales set the close against that year's balance sheet in dollars at its year-end rate and its share count per US share. The dashed line is the median over the range shown. The P/E above uses today's exchange rate, so the latest point here can differ from it a little. Drawn in your browser; the range and overlay you pick are remembered here only.The public record on TAK
| Dividends | JPY 312 billion paid in cash dividends in FY2026 |
| Filings | 36 in twelve months: 34 reports on Form 6-K, most often financial appendix (4); U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations (1); takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera (1); U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 (1); corporate Governance Report (1) |
| Planned insider sales | 24 Form 144 notices in twelve months, $18.1 million; latest 30 October 2026 |
| Options tape | put/call 0.76 by open interest at the 10 November 2026 close; the straddle prices a 13.9% move to 20 November 2026 |
| 13F holders | 382 funds reported a position for the quarter to 30 June 2026; largest Capital Research Global Investors |
| Insider trading | 22 sales and 0 purchases on Form 4 in twelve months |
| Congress | 0 House trades disclosed in six months |
| Short interest | 3.1 million shares short, 1.02 days to cover at 30 October 2026 |
Income statement (profit and loss), 10 fiscal years
Figures in
Play it forward: change any box and its column follows; every box opens at the company's own record, shown under the row's name, and says when you set it outside every year in the table.
Read more
Each column runs from the latest year filed to the year chosen in its heading, at a yearly rate. Sales growth starts at the company's own five-year rate and eases a third of the way each year toward the median of the 130 peers in Pharmaceutical Products (15.6% a year), because a rate far from the rest rarely lasts. Before you open a year, the strip reads today's price backwards: the yearly sales growth that brings EPS, at the company's own margins, tax and share count, to today's price at the median P/E of the 65 peers in Pharmaceutical Products (25.1). Low, middle, high opens three columns for one year: the low and high cases take the company's own weaker and stronger years in the table (the lower and upper quarter of its yearly sales growth and operating margin) and the lower and higher of today's P/E and its peers'; the middle is the boxes as they open. Net income keeps the share that went to minority holders; EPS is net income over the diluted shares, on the same basis as the EPS in the table. The price is that year's EPS at the P/E you set, and the yearly return runs from today's price to the year's end. These are your assumptions and your arithmetic, not an estimate of ours. The link carries your columns, so you can send the forecast to someone.| Year to | Mar 2017 | Mar 2018 | Mar 2019 † | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,732 | 1,771 | 2,097 | 3,291 | 3,198 | 3,569 | 4,027 | 4,264 | 4,582 | 4,506 |
| Cost of sales | 559 | 496 | 652 | 1,090 | 994 | 1,107 | 1,244 | 1,427 | 1,580 | 1,572 |
| Research and development | 312 | 325 | 368 | 492 | 456 | 526 | 633 | 730 | 730 | 676 |
| Operating profit | 156 | 242 | 238 | 100 | 509 | 461 | 491 | 214 | 343 | 6.2 |
| Finance costs | 23.2 | 31.9 | 83.3 | 165 | 249 | 167 | 170 | 220 | 210 | 358 |
| Profit before tax | 143 | 217 | 128 | -60.8 | 366 | 303 | 375 | 52.8 | 175 | -142 |
| Income tax | 27.8 | 30.5 | -7.5 | -105 | -9.9 | 72.4 | 58.1 | -91.4 | 66.9 | 9.8 |
| Profit for the year | 116 | 187 | 135 | 44.3 | 376 | 230 | 317 | 144 | 108 | -152 |
| Profit attributable to shareholders | 115 | 187 | 135 | 44.2 | 376 | 230 | 317 | 144 | 108 | -152 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F |
JPY billion, from each year's annual report on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read more
A line the company does not file under the standard tag is left out rather than estimated. A year marked † shows the figure as the company restated it in a later annual report (Mar 2019); the first-filed figure is in the CSV. Profit for the year includes the part that belongs to minority shareholders; profit attributable to shareholders is the part EPS is struck on. Each year links to its own page.| Year to | Mar 2017 | Mar 2018 | Mar 2019 † | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS | 146.26 | 237.56 | 139.82 | 28.25 | 238.96 | 145.87 | 201.94 | 91.16 | 67.23 | -96.75 |
| Basic EPS | 147.15 | 239.35 | 140.61 | 28.41 | 240.72 | 147.14 | 204.29 | 92.09 | 68.36 | -96.75 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F |
JPY per ordinary share, as filed. One US-listed share can stand for more or fewer ordinary shares; the P/E above puts the two on the same basis.
Revenue by product or service
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales of pharmaceutical products | 1,672 | 1,694 | 2,026 | 3,204 | 3,105 | 3,296 | 3,922 | 4,164 | 4,496 | 4,423 | 98.2% |
| Out-licensing and service income | 60.1 | 76.7 | 71.0 | 87.0 | 92.4 | 273 | 105 | 100 | 85.6 | 82.6 | 1.8% |
Sales of pharmaceutical productsOut-licensing and service income
JPY billion; hover a block for its figure and share
JPY billion, from the latest 20-F, in the company's own words. A year is shown only where the parts add up to the revenue above.
Revenue by region
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 520 | 598 | 829 | 1,596 | 1,568 | 1,714 | 2,104 | 2,196 | 2,380 | 2,165 | 48.0% |
| Europe and Canada | 280 | 314 | 406 | 646 | 666 | 739 | 843 | 967 | 1,055 | 1,146 | 25.4% |
| Japan | 655 | 580 | 571 | 593 | 560 | 659 | 512 | 451 | 418 | 433 | 9.6% |
| Latin America | 72.5 | 75.7 | 88.1 | 143 | 122 | 128 | 160 | 198 | 236 | 254 | 5.6% |
| China | n/a | n/a | n/a | n/a | n/a | n/a | 151 | 175 | 192 | 195 | 4.3% |
| Other | 34.0 | 30.2 | 38.3 | 71.3 | 68.5 | 68.9 | 95.2 | 118 | 129 | 134 | 3.0% |
| Asia (excluding Japan & China) | n/a | n/a | n/a | n/a | n/a | n/a | 74.0 | 86.4 | 99.4 | 98.7 | 2.2% |
| Russia/CIS | 57.5 | 68.2 | 59.7 | 76.8 | 57.6 | 62.1 | 88.4 | 72.6 | 72.4 | 79.7 | 1.8% |
| Asia | 113 | 104 | 105 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Asia (excluding Japan) | n/a | n/a | n/a | 165 | 156 | 197 | n/a | n/a | n/a | n/a | n/a |
United StatesEurope and CanadaJapanLatin AmericaChina FY2023 to FY2026OtherAsia (excluding Japan & China) FY2023 to FY2026Russia/CISAsia (excluding Japan) FY2020 to FY2022Asia FY2017 to FY2019
JPY billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then
JPY billion, from the latest 20-F, in the company's own words. A year is shown only where the parts add up to the revenue above.
Cash flow statement
Follow the cash: free cash flow, which is operating cash flow less capital expenditure and share-based pay, for five years and after, in today's money.
Read more
The figure a share at the top is what a discounted cash flow calls intrinsic value, worked out on your assumptions. Everything after year five is one sum: the sixth year's cash, growing at the long-run rate every year after, added up and brought back to today's money. Each year runs from the latest year filed. Sales growth opens where Play it forward does: the company's own five-year rate, easing a third of the way each year toward the median of the 130 peers in Pharmaceutical Products (15.6% a year); change a year and the years after it follow. Operating cash flow, capital expenditure and share-based pay open at the company's own median share of sales over its last five years, shown under each row. Share-based pay is taken off because operating cash flow adds back the shares paid to staff as if they cost nothing; set it to 0 to leave it in. Capital spending counts every capital line the company files in its cash flow, such as equipment it leases to customers, software, wells or property it develops, named under the row, while the Capital expenditure row in the table below stays the one line as filed; buying a business, securities or a finished property is not counted. The discount rate opens at 10%, about what US stocks have returned a year over the long run, so it is the return you give up by holding this company instead of the market; the growth after year five opens at 3%, a little under the US economy's long-run growth in dollars, because no company outgrows it for ever. Net debt is the debt and short-term borrowings less the cash on the latest balance sheet that shows the debt; the figure per share divides what is left by the diluted share count. These are your assumptions and your arithmetic, not an estimate of ours. The link carries them, so you can send them to someone.| Year to | Mar 2017 | Mar 2018 | Mar 2019 † | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 261 | 378 | 328 | 670 | 1,011 | 1,123 | 977 | 716 | 1,057 | 1,041 |
| Purchase of property, plant and equipment | 61.7 | 67.0 | 77.7 | 127 | 111 | 123 | 141 | 175 | 201 | 176 |
| Free cash flow | 200 | 311 | 251 | 543 | 900 | 1,000 | 836 | 541 | 856 | 865 |
| Cash from investing | -656 | -93.3 | -2,836 | 292 | 394 | -198 | -607 | -464 | -367 | -369 |
| Cash from financing | 290 | -326 | 2,946 | -1,005 | -1,088 | -1,070 | -709 | -354 | -751 | -497 |
| Depreciation and amortisation | 171 | 182 | 248 | 584 | 560 | 583 | 664 | 728 | 761 | 721 |
| Buybacks | 23.1 | 18.8 | 1.2 | 3.7 | 2.1 | 77.5 | 26.9 | 2.3 | 51.9 | 51.6 |
| Dividends paid | 142 | 142 | 143 | 283 | 283 | 284 | 279 | 287 | 302 | 312 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F |
JPY billion, from the cash flow statement as filed.
Read more
Purchase of property, plant and equipment is the cash line as filed; purchases of intangible assets and acquisitions are not in it. Free cash flow is cash from operations less that purchase, arithmetic on the two filed lines. Cash from investing and from financing are the company's own section totals, below zero where cash went out. Buybacks are the cash paid for the company's own shares.Balance sheet at year end
| Year to | Mar 2017 | Mar 2018 | Mar 2019 † | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Funded by | ||||||||||
| Equity attributable to shareholders | 1,949 | 1,997 | 5,182 | 4,723 | 5,173 | 5,683 | 6,354 | 7,273 | 6,935 | 7,429 |
| Non-controlling interests | n/a | 20.0 | 4.0 | 4.0 | 4.1 | 0.5 | 0.5 | 0.7 | 0.9 | 1.2 |
| Borrowings, as filed | n/a | 986 | 5,751 | 5,093 | 4,635 | 4,345 | 4,382 | 4,844 | 4,515 | 4,882 |
| Lease liabilities | n/a | n/a | 0.0 | 369 | 436 | 465 | 479 | 620 | 573 | 595 |
| Other liabilities | n/a | 1,103 | 2,856 | 2,631 | 2,663 | 2,684 | 2,741 | 2,371 | 2,224 | 2,604 |
| Total equity and liabilities | n/a | 4,106 | 13,793 | 12,821 | 12,912 | 13,178 | 13,958 | 15,109 | 14,248 | 15,512 |
| Owned | ||||||||||
| Property, plant and equipment | n/a | 537 | 1,332 | 1,386 | 1,454 | 1,583 | 1,691 | 1,990 | 1,968 | 2,121 |
| Goodwill | n/a | 1,029 | 4,240 | 4,013 | 4,034 | 4,408 | 4,791 | 5,410 | 5,324 | 5,809 |
| Other intangible assets | n/a | 1,014 | 4,751 | 4,171 | 3,909 | 3,819 | 4,270 | 4,275 | 3,632 | 3,419 |
| Cash and cash equivalents | 319 | 295 | 702 | 638 | 966 | 850 | 534 | 458 | 385 | 595 |
| Trade and other receivables | n/a | 420 | 742 | 757 | 783 | 697 | 649 | 668 | 709 | 844 |
| Inventories | n/a | 213 | 920 | 760 | 754 | 853 | 986 | 1,210 | 1,217 | 1,397 |
| Other assets | n/a | 598 | 1,106 | 1,097 | 1,012 | 969 | 1,037 | 1,098 | 1,012 | 1,327 |
| Total assets | n/a | 4,106 | 13,793 | 12,821 | 12,912 | 13,178 | 13,958 | 15,109 | 14,248 | 15,512 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F |
JPY billion, at each fiscal year end.
Read more
Both totals are the company's own; other liabilities and other assets are each total less the rows shown. Borrowings is the company's own stated total where it files one; it is never added up from its parts here.Ratios on the filed lines
| Year to | Mar 2017 | Mar 2018 | Mar 2019 † | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 9.0% | 13.7% | 11.3% | 3.1% | 15.9% | 12.9% | 12.2% | 5.0% | 7.5% | 0.1% |
| Net margin | 6.6% | 10.6% | 6.4% | 1.3% | 11.8% | 6.4% | 7.9% | 3.4% | 2.4% | -3.4% |
| Free cash flow margin | 11.5% | 17.6% | 12.0% | 16.5% | 28.1% | 28.0% | 20.8% | 12.7% | 18.7% | 19.2% |
| Return on year-end equity | 5.9% | 9.4% | 2.6% | 0.9% | 7.3% | 4.0% | 5.0% | 2.0% | 1.6% | -2.1% |
| Effective tax rate | 19.4% | 14.0% | -5.9% | n/a | -2.7% | 23.9% | 15.5% | -173.1% | 38.2% | n/a |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F |
Arithmetic on the filed lines of the same year: margins over revenue, return on equity as profit attributable to shareholders over year-end equity, tax over profit before tax.
Questions
What was Takeda Pharmaceutical's revenue in the year to 31 March 2026?
Takeda Pharmaceutical (TAK) reported revenue of JPY 4.51 trillion for the year to 31 March 2026, down 1.7% on the year before.
How much did Takeda Pharmaceutical earn in the year to 31 March 2026?
Loss attributable to shareholders was JPY 152 billion for the year to 31 March 2026, and the diluted loss per share JPY 96.75.
What is Takeda Pharmaceutical's market cap?
The market cap of Takeda Pharmaceutical was $66.1 billion at the close of 10 November 2026.
The exchange rates used
| Year to | Average over the year JPY per US dollar | At the year end JPY per US dollar |
|---|---|---|
| Mar 2017 | 108.00 | 111.41 |
| Mar 2018 | 110.75 | 106.20 |
| Mar 2019 | 110.86 | 110.68 |
| Mar 2020 | 108.70 | 107.53 |
| Mar 2021 | 106.06 | 110.61 |
| Mar 2022 | 112.24 | 121.44 |
| Mar 2023 | 135.17 | 132.75 |
| Mar 2024 | 144.31 | 151.22 |
| Mar 2025 | 152.25 | 149.90 |
| Mar 2026 | 150.48 | 159.08 |
Converted by us, not by the company: the Federal Reserve's daily noon buying rates in New York (H.10), FRED series DEXJPUS.
Read more
Profit and loss, cash flow and EPS use the average of the daily rates over each fiscal year; the balance sheet uses the rate on the year end, or the last one before it. Ratios are the same in either currency. The filed figures are the ones in yen.Peers: Pharmaceutical Products
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Eli Lilly & Co. LLY | $1.35 trillion | 46.51 | 68.5% | n/a | 45.5% | 1.23 | 0.4% |
| Johnson & Johnson JNJ | $675.9 billion | 42.54 | 19.7% | n/a | 7.8% | 0.55 | 1.9% |
| AbbVie Inc. ABBV | $519.4 billion | 50.58 | n/a | 32.2% | 10.7% | n/a | 2.4% |
| Merck & Co., Inc. MRK | $364.8 billion | 152.57 | 5.5% | n/a | 4.9% | 1.20 | 2.3% |
| Novartis AG NVS * | $311.5 billion | 22.83 | 30.3% | n/a | 8.4% | 0.62 | 2.5% |
| AstraZeneca PLC AZN * | $289.7 billion | 28.56 | 21.0% | 23.4% | 8.6% | 0.57 | 1.7% |
| Abbott Laboratories ABT | $191.3 billion | 41.21 | 9.2% | 13.8% | 10.0% | 0.61 | 2.3% |
| Novo Nordisk A/S NVO * | $181.7 billion | 11.84 | 52.8% | 41.3% | 6.4% | 0.67 | 4.3% |
| Pfizer Inc. PFE | $167.3 billion | 41.94 | 4.5% | n/a | 1.3% | 0.70 | 5.9% |
| Vertex Pharmaceuticals Inc. VRTX | $138.9 billion | 35.24 | 19.0% | 33.2% | 10.5% | 0.22 | n/a |
| Bristol-Myers Squibb Co. BMY | $128.4 billion | 13.92 | 39.5% | 22.6% | 4.2% | 1.83 | 4.0% |
| Sanofi SNY * | $117.6 billion | 13.57 | 10.9% | n/a | 6.2% | 0.26 | 4.6% |
All 174 in Pharmaceutical Products
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Eli Lilly & Co. LLY | $1.35 trillion | 46.51 | 68.5% | n/a | 45.5% | 1.23 | 0.4% |
| Johnson & Johnson JNJ | $675.9 billion | 42.54 | 19.7% | n/a | 7.8% | 0.55 | 1.9% |
| AbbVie Inc. ABBV | $519.4 billion | 50.58 | n/a | 32.2% | 10.7% | n/a | 2.4% |
| Merck & Co., Inc. MRK | $364.8 billion | 152.57 | 5.5% | n/a | 4.9% | 1.20 | 2.3% |
| Novartis AG NVS * | $311.5 billion | 22.83 | 30.3% | n/a | 8.4% | 0.62 | 2.5% |
| AstraZeneca PLC AZN * | $289.7 billion | 28.56 | 21.0% | 23.4% | 8.6% | 0.57 | 1.7% |
| Amgen Inc. AMGN | $251.6 billion | 26.98 | 65.4% | 32.4% | 8.2% | 3.76 | 2.2% |
| Gilead Sciences, Inc. GILD | $212.1 billion | n/a | -29.6% | -7.6% | 6.5% | 2.01 | 1.9% |
| Abbott Laboratories ABT | $191.3 billion | 41.21 | 9.2% | 13.8% | 10.0% | 0.61 | 2.3% |
| Novo Nordisk A/S NVO * | $181.7 billion | 11.84 | 52.8% | 41.3% | 6.4% | 0.67 | 4.3% |
| Pfizer Inc. PFE | $167.3 billion | 41.94 | 4.5% | n/a | 1.3% | 0.70 | 5.9% |
| Vertex Pharmaceuticals Inc. VRTX | $138.9 billion | 35.24 | 19.0% | 33.2% | 10.5% | 0.22 | n/a |
| Bristol-Myers Squibb Co. BMY | $128.4 billion | 13.92 | 39.5% | 22.6% | 4.2% | 1.83 | 4.0% |
| Sanofi SNY * | $117.6 billion | 13.57 | 10.9% | n/a | 6.2% | 0.26 | 4.6% |
| GSK plc GSK * | $102.8 billion | 13.80 | 34.9% | 24.3% | 4.1% | 1.08 | 3.3% |
| Moderna, Inc. MRNA | $101.3 billion | n/a | -40.8% | -116.0% | 13.1% | 0.52 | n/a |
| Regeneron Pharmaceuticals, Inc. REGN | $96.8 billion | 20.23 | 14.4% | 28.8% | 18.6% | 0.06 | 0.4% |
| Takeda Pharmaceutical Company Limited TAK * | $66.1 billion | n/a | -2.1% | 0.1% | -1.7% | 0.66 | 3.1% |
| argenx SE ARGX * | $60.1 billion | 49.66 | 17.6% | n/a | 89.9% | 0.00 | n/a |
| IDEXX Laboratories Inc. IDXX | $54.9 billion | 46.95 | 63.2% | 32.3% | 11.9% | 0.45 | n/a |
| Teva Pharmaceutical Industries Ltd. TEVA | $49.5 billion | 98.59 | 6.4% | 8.3% | 2.7% | 2.10 | n/a |
| Royalty Pharma plc RPRX | $38.7 billion | 45.69 | 6.9% | 57.1% | 11.4% | 0.88 | 1.3% |
| Biogen Inc. BIIB | $37.4 billion | 108.21 | 1.8% | 4.3% | 2.3% | 0.41 | n/a |
| Genmab A/S GMAB * | $34.7 billion | 35.19 | 16.5% | 28.6% | 19.2% | 0.90 | n/a |
| Zoetis Inc. ZTS | $33.6 billion | 14.02 | 75.3% | n/a | 1.0% | 2.74 | 2.5% |
| Roivant Sciences Ltd. ROIV | $29.8 billion | n/a | -8.6% | -1,358.1% | 102.1% | 0.00 | n/a |
| Insmed Inc. INSM | $26.2 billion | n/a | -83.4% | -37.1% | 240.0% | 0.76 | n/a |
| United Therapeutics Corp. UTHR | $24.9 billion | 22.19 | 19.6% | 41.4% | 1.9% | 0.00 | n/a |
| Viatris Inc. VTRS | $23.9 billion | n/a | -4.4% | -0.0% | 4.3% | 0.97 | 2.3% |
| BioNTech SE BNTX * | $21.9 billion | n/a | -5.9% | -49.0% | 4.3% | 0.01 | n/a |
| Alnylam Pharmaceuticals, Inc. ALNY | $20.3 billion | 7.87 | 75.6% | 19.5% | 56.2% | 0.28 | n/a |
| Exelixis, Inc. EXEL | $17.3 billion | 21.12 | 48.3% | 40.2% | 9.1% | 0.00 | n/a |
| Neurocrine Biosciences Inc. NBIX | $17.1 billion | 25.09 | 18.1% | 24.0% | 38.0% | 0.00 | n/a |
| Jazz Pharmaceuticals plc JAZZ | $15.8 billion | 83.52 | 4.9% | 9.0% | 13.5% | 1.33 | n/a |
| BridgeBio Pharma, Inc. BBIO | $15.4 billion | n/a | n/a | -38.5% | 167.3% | n/a | n/a |
| Kiniksa Pharmaceuticals International, plc KNSA | $14.9 billion | 73.14 | 15.4% | 13.8% | 58.2% | 0.00 | n/a |
| Elanco Animal Health Inc. ELAN | $13.4 billion | n/a | -2.2% | n/a | 12.1% | 0.52 | n/a |
| Dr. Reddy’s Laboratories Limited RDY * | $12.4 billion | 27.15 | 11.4% | 15.0% | 3.2% | 0.21 | 0.6% |
| Halozyme Therapeutics, Inc. HALO | $11.7 billion | 26.22 | n/a | 37.4% | 45.0% | n/a | n/a |
| Kymera Therapeutics, Inc. KYMR | $11.7 billion | n/a | -21.6% | -396.0% | 133.8% | 0.00 | n/a |
| Bio-Techne Corp. TECH | $11.4 billion | 66.81 | 7.9% | 19.6% | 0.9% | 0.09 | 0.4% |
| Biomarin Pharmaceutical Inc. BMRN | $11.1 billion | n/a | -0.3% | 3.1% | 18.1% | 0.67 | n/a |
| Madrigal Pharmaceuticals, Inc. MDGL | $10.0 billion | n/a | -24.8% | -10.7% | 92.8% | 0.54 | n/a |
| Repligen Corp. RGEN | $9.9 billion | n/a | -0.6% | 2.3% | 13.8% | 0.27 | n/a |
| TG Therapeutics, Inc. TGTX | $9.7 billion | 97.39 | 18.5% | 21.5% | 68.8% | 1.30 | n/a |
| Krystal Biotech, Inc. KRYS | $9.1 billion | 41.60 | 15.7% | 48.4% | 26.0% | 0.00 | n/a |
| Protagonist Therapeutics, Inc. PTGX | $8.9 billion | 28.85 | 31.5% | 58.6% | 163.7% | 0.00 | n/a |
| Twist Bioscience Corp. TWST | $8.3 billion | n/a | -30.7% | -33.6% | 19.2% | 0.03 | n/a |
| Corcept Therapeutics Inc. CORT | $8.0 billion | 57.76 | 19.5% | 11.5% | 30.0% | 0.00 | n/a |
| Rhythm Pharmaceuticals, Inc. RYTM | $7.9 billion | n/a | -220.3% | -66.7% | 61.0% | 1.17 | n/a |
| Cytokinetics Inc. CYTK | $7.8 billion | n/a | n/a | -625.2% | 29.9% | n/a | n/a |
| Alkermes plc. ALKS | $7.8 billion | n/a | -0.0% | 3.7% | 15.3% | 0.81 | n/a |
| Amneal Pharmaceuticals, Inc. AMRX | $7.5 billion | 50.93 | 25.1% | 15.0% | 8.9% | 5.87 | n/a |
| Axsome Therapeutics, Inc. AXSM | $7.4 billion | n/a | -149.2% | -17.5% | 54.2% | 1.78 | n/a |
| ImmunityBio, Inc. IBRX | $7.2 billion | n/a | n/a | -150.2% | 121.2% | n/a | n/a |
| Arrowhead Pharmaceuticals, Inc. ARWR | $6.9 billion | n/a | -68.7% | -33.8% | 16.8% | 1.86 | n/a |
| Lantheus Holdings, Inc. LNTH | $6.6 billion | 25.03 | 19.9% | 18.6% | 2.4% | 0.42 | n/a |
| CG Oncology, Inc. CGON | $6.5 billion | n/a | -24.0% | -4,293.5% | 183.6% | 0.00 | n/a |
| Ligand Pharmaceuticals Inc. LGND | $6.3 billion | 140.12 | 5.4% | 9.5% | 1.0% | 1.17 | n/a |
| Mirum Pharmaceuticals, Inc. MIRM | $6.2 billion | n/a | n/a | -133.6% | 42.2% | n/a | n/a |
| Scholar Rock Holding Corp. SRRK | $5.9 billion | n/a | n/a | n/a | n/a | 1.16 | n/a |
| PTC Therapeutics, Inc. PTCT | $5.4 billion | n/a | n/a | 12.8% | -35.1% | n/a | n/a |
| Travere Therapeutics, Inc. TVTX | $5.0 billion | n/a | -538.0% | -20.5% | 49.4% | 26.72 | n/a |
| Adaptive Biotechnologies Corp. ADPT | $4.7 billion | n/a | -40.0% | -16.2% | 17.9% | 1.90 | n/a |
| Ionis Pharmaceuticals Inc. IONS | $4.7 billion | n/a | -138.8% | -58.8% | -0.7% | 3.36 | n/a |
| Liquidia Corp. LQDA | $4.6 billion | n/a | n/a | -15.6% | 798.4% | n/a | n/a |
| Relay Therapeutics, Inc. RLAY | $4.4 billion | n/a | -35.9% | -3,094.9% | 23.9% | 0.00 | n/a |
| Crispr Therapeutics AG CRSP | $4.4 billion | n/a | -27.7% | -2,114.8% | -34.3% | 0.36 | n/a |
| Tango Therapeutics, Inc. TNGX | $4.1 billion | n/a | -21.2% | n/a | n/a | 0.00 | n/a |
| AbCellera Biologics Inc. ABCL | $4.1 billion | n/a | -14.0% | -298.0% | 92.1% | 0.00 | n/a |
| Xenon Pharmaceuticals Inc. XENE | $4.1 billion | n/a | -37.4% | n/a | n/a | 0.00 | n/a |
| Iovance Biotherapeutics, Inc. IOVA | $3.7 billion | n/a | -27.1% | -60.8% | 51.3% | 0.00 | n/a |
| Viking Therapeutics, Inc. VKTX | $3.7 billion | n/a | -106.6% | n/a | n/a | 0.43 | n/a |
| Organon & Co. OGN | $3.6 billion | 18.27 | 17.9% | n/a | -3.2% | 7.17 | 0.6% |
| Tarsus Pharmaceuticals, Inc. TARS | $3.6 billion | n/a | -675.0% | -102.0% | 86.3% | 0.70 | 0.0% |
| DBV Technologies S.A. DBVT | $3.6 billion | n/a | -139.5% | -5,420.1% | -31.5% | 0.00 | n/a |
| Viridian Therapeutics, Inc. VRDN | $3.5 billion | n/a | -78.1% | -1,781.4% | -62.8% | 0.63 | n/a |
| Arcutis Biotherapeutics, Inc. ARQT | $3.5 billion | 130.57 | 12.3% | 6.9% | 60.0% | 0.45 | n/a |
| Supernus, Inc. SUPN | $3.4 billion | 8.03 | n/a | 40.6% | 16.4% | n/a | n/a |
| Denali Therapeutics Inc. DNLI | $3.2 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Acadia Pharmaceuticals Inc. ACAD | $3.2 billion | 8.66 | 26.1% | 10.2% | 14.8% | 0.00 | n/a |
| Bausch Health Companies Inc. BHC | $3.1 billion | n/a | n/a | 11.2% | 10.8% | n/a | n/a |
| Ideaya Biosciences, Inc. IDYA | $3.1 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Vericel Corp. VCEL | $3.0 billion | 92.27 | 8.7% | 8.3% | 25.3% | 0.00 | n/a |
| Xencor Inc. XNCR | $2.9 billion | n/a | -21.0% | -72.7% | 33.5% | 0.17 | n/a |
| Xeris Biopharma Holdings, Inc. XERS | $2.9 billion | n/a | -13.3% | 12.7% | 38.4% | 3.89 | n/a |
| Adma Biologics, Inc. ADMA | $2.8 billion | 16.44 | 41.6% | 46.5% | 6.3% | 0.45 | n/a |
| Silence Therapeutics plc SLN | $2.8 billion | n/a | -155.8% | -11,106.8% | -97.7% | 0.00 | n/a |
| Beam Therapeutics Inc. BEAM | $2.6 billion | n/a | -11.2% | -267.7% | 163.3% | 0.11 | n/a |
| Neogen Corp. NEOG | $2.5 billion | n/a | -2.7% | -0.8% | -0.3% | 0.37 | n/a |
| Septerna, Inc. SEPN | $2.5 billion | n/a | -13.8% | -76.2% | 336.7% | 0.00 | n/a |
| Schrodinger, Inc. SDGR | $2.4 billion | n/a | -19.6% | -49.6% | 4.8% | 0.00 | n/a |
| Celldex Therapeutics, Inc. CLDX | $2.4 billion | n/a | -47.6% | -213,033.8% | -94.0% | 0.00 | n/a |
| Arcus Biosciences, Inc. RCUS | $2.4 billion | n/a | -126.5% | -475.0% | -58.3% | 0.28 | n/a |
| Perrigo Co. plc PRGO | $2.3 billion | n/a | -72.5% | -39.4% | -4.5% | 1.35 | 6.9% |
| NewAmsterdam Pharma Co. N.V. NAMS | $2.3 billion | n/a | -32.5% | -900.1% | -26.4% | 0.00 | n/a |
| Zymeworks Inc. ZYME | $2.2 billion | 60.50 | 16.8% | 16.6% | 97.8% | 1.31 | n/a |
| Vir Biotechnology, Inc. VIR | $2.2 billion | n/a | -20.6% | -69.8% | 1,696.0% | 0.00 | n/a |
| Aurinia Pharmaceuticals Inc. AUPH | $2.2 billion | 7.12 | 47.8% | 48.6% | 21.0% | 0.00 | n/a |
| Prestige Consumer Healthcare Inc. PBH | $2.1 billion | 13.89 | 8.0% | 25.0% | 5.1% | 1.07 | n/a |
| Immunome Inc. IMNM | $2.1 billion | n/a | -62.2% | n/a | n/a | 0.00 | n/a |
| Maze Therapeutics, Inc. MAZE | $2.0 billion | n/a | n/a | n/a | n/a | 0.09 | n/a |
| Recursion Pharmaceuticals, Inc. RXRX | $2.0 billion | n/a | -52.5% | -725.4% | 56.2% | 0.01 | n/a |
| Harmony Biosciences Holdings, Inc. HRMY | $2.0 billion | 11.11 | 16.7% | 22.2% | 19.8% | 0.14 | n/a |
| Eton Pharmaceuticals, Inc. ETON | $1.9 billion | 44.36 | 57.4% | 28.8% | 100.6% | 0.27 | n/a |
| Zenas BioPharma, Inc. ZBIO | $1.9 billion | n/a | n/a | n/a | n/a | 1.41 | n/a |
| Biocryst Pharmaceuticals Inc. BCRX | $1.9 billion | n/a | n/a | -30.1% | 60.3% | n/a | n/a |
| Agios Pharmaceuticals, Inc. AGIO | $1.9 billion | n/a | -38.1% | -297.7% | 214.4% | 0.00 | n/a |
| Trulieve Cannabis Corp. TRLV | $1.9 billion | n/a | -57.8% | -25.6% | -9.1% | 0.37 | n/a |
| Generate Biomedicines, Inc. GENB | $1.8 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Stoke Therapeutics, Inc. STOK | $1.8 billion | n/a | -69.0% | -913.1% | -86.3% | 0.00 | n/a |
| Sarepta Therapeutics, Inc. SRPT | $1.8 billion | n/a | -7.5% | -2.5% | -18.9% | 0.56 | n/a |
| Nurix Therapeutics, Inc. NRIX | $1.7 billion | 6.87 | 30.5% | 41.3% | 738.8% | 0.00 | 0.0% |
| Novavax Inc. NVAX | $1.7 billion | n/a | n/a | -21.2% | -61.3% | n/a | n/a |
| Immunocore Holdings plc IMCR | $1.7 billion | n/a | -7.7% | -6.8% | 13.1% | 0.94 | 0.0% |
| Ultragenyx Pharmaceutical Inc. RARE | $1.6 billion | n/a | n/a | -64.0% | 15.8% | n/a | n/a |
| Precigen, Inc. PGEN | $1.6 billion | 129.20 | 29.1% | 21.4% | n/a | 1.12 | n/a |
| ANI Pharmaceuticals Inc. ANIP | $1.6 billion | 14.03 | 18.3% | 16.0% | 25.9% | 0.95 | n/a |
| uniQure N.V. QURE | $1.6 billion | n/a | -79.0% | -1,001.7% | 28.0% | 0.17 | n/a |
| Intellia Therapeutics, Inc. NTLA | $1.6 billion | n/a | -69.5% | -821.2% | -8.1% | 0.12 | n/a |
| Nuvation Bio Inc. NUVB | $1.5 billion | n/a | -59.6% | -61.2% | 654.2% | 1.25 | n/a |
| Pacira BioSciences, Inc. PCRX | $1.5 billion | 39.23 | 5.3% | 4.8% | 3.7% | 0.41 | n/a |
| Ocular Therapeutix, Inc. OCUL | $1.5 billion | n/a | -74.1% | -680.9% | -9.7% | 0.17 | n/a |
| Phibro Animal Health Corp. PAHC | $1.4 billion | 13.85 | 24.6% | 12.5% | 10.1% | 1.76 | 1.4% |
| Korsana Biosciences, Inc. KRSA | $1.4 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Taysha Gene Therapies, Inc. TSHA | $1.4 billion | n/a | -38.6% | -2,792.3% | -32.3% | 0.13 | n/a |
| Avalyn Pharma Inc. AVLN | $1.4 billion | n/a | n/a | n/a | n/a | 0.04 | n/a |
| Innoviva, Inc. INVA | $1.4 billion | 9.59 | 17.0% | 38.8% | 12.8% | 0.23 | n/a |
| Mannkind Corp. MNKD | $1.4 billion | n/a | n/a | -2.9% | 31.7% | n/a | n/a |
| Inhibrx Biosciences, Inc. INBX | $1.3 billion | n/a | n/a | n/a | n/a | n/a | n/a |
| Opko Health, Inc. OPK | $1.3 billion | n/a | -13.3% | -25.5% | -21.9% | 0.43 | n/a |
| Cronos Group Inc. CRON | $1.3 billion | 20.06 | 5.4% | 3.4% | 55.8% | 0.00 | n/a |
| Rapport Therapeutics, Inc. RAPP | $1.2 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Omeros Corp. OMER | $1.2 billion | n/a | n/a | n/a | n/a | n/a | n/a |
| UroGen Pharma Ltd. URGN | $1.2 billion | n/a | n/a | -12.4% | 159.3% | n/a | n/a |
| Amphastar Pharmaceuticals, Inc. AMPH | $1.2 billion | 13.28 | 12.1% | 18.7% | 3.1% | 0.75 | n/a |
| Harrow, Inc. HROW | $1.1 billion | n/a | -97.6% | -2.0% | 21.3% | 10.03 | n/a |
| Cryoport, Inc. CYRX | $1.1 billion | n/a | -7.8% | -20.0% | 1.1% | 0.39 | n/a |
| Odyssey Therapeutics, Inc. ODTX | $957 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Aktis Oncology, Inc. AKTS | $934 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| MeiraGTx Holdings plc MGTX | $906 million | 13.54 | 36.6% | 46.3% | 948.3% | 0.46 | n/a |
| Monte Rosa Therapeutics, Inc. GLUE | $896 million | n/a | -26.4% | -214.5% | -61.3% | 0.00 | n/a |
| Syndax Pharmaceuticals Inc. SNDX | $851 million | n/a | n/a | -61.7% | 159.5% | n/a | n/a |
| Lexicon Pharmaceuticals, Inc. LXRX | $838 million | n/a | -38.1% | -147.4% | -45.6% | 0.32 | n/a |
| Rigel Pharmaceuticals Inc. RIGL | $827 million | 2.83 | 69.0% | 26.3% | 2.2% | 0.02 | n/a |
| Verastem, Inc. VSTM | $824 million | n/a | n/a | n/a | n/a | 11.82 | n/a |
| Ironwood Pharmaceuticals Inc. IRWD | $797 million | 5.35 | n/a | 62.9% | 18.1% | n/a | n/a |
| QuidelOrtho Corp. QDEL | $791 million | n/a | -20.6% | -4.9% | -4.5% | 1.64 | n/a |
| Ginkgo Bioworks Holdings, Inc. DNA | $775 million | n/a | -63.9% | -242.5% | -44.2% | 0.00 | n/a |
| Nektar Therapeutics NKTR | $770 million | n/a | -17.4% | -257.8% | -27.2% | 0.00 | n/a |
| Arbutus Biopharma Corp. ABUS | $762 million | 3.38 | 256.5% | 81.1% | 1,142.6% | 0.00 | n/a |
| Collegium Pharmaceutical, Inc. COLL | $760 million | 24.46 | 12.9% | 15.2% | 7.7% | 3.65 | n/a |
| Ardelyx, Inc. ARDX | $754 million | n/a | -33.8% | -7.7% | 17.6% | 1.54 | n/a |
| Janux Therapeutics, Inc. JANX | $736 million | n/a | -11.0% | -599.3% | 132.9% | 0.00 | n/a |
| Zevra Therapeutics, Inc. ZVRA | $709 million | 9.86 | 32.7% | 60.8% | 75.1% | 0.00 | n/a |
| Kura Oncology, Inc. KURA | $695 million | n/a | -1,630.7% | -394.3% | n/a | 0.55 | n/a |
| Design Therapeutics, Inc. DSGN | $679 million | n/a | -36.6% | n/a | n/a | 0.00 | n/a |
| Wave Life Sciences, Inc. WVE | $671 million | n/a | -52.4% | -320.9% | n/a | 0.00 | n/a |
| Geron Corp. GERN | $627 million | n/a | n/a | n/a | n/a | 0.53 | n/a |
| Aclaris Therapeutics, Inc. ACRS | $626 million | n/a | -47.7% | -1,414.0% | -59.3% | 0.00 | n/a |
| Myriad Genetics Inc. MYGN | $541 million | n/a | -48.0% | -14.3% | -2.6% | 0.45 | n/a |
| Monopar Therapeutics MNPR | $481 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Arvinas, Inc. ARVN | $452 million | n/a | -1.8% | -12.1% | -11.8% | 0.00 | n/a |
| Gyre Therapeutics, Inc. GYRE | $452 million | n/a | -37.5% | -20.6% | 13.5% | 0.00 | n/a |
| Evolus, Inc. EOLS | $450 million | n/a | n/a | -4.8% | 13.9% | n/a | n/a |
| Phathom Pharmaceuticals, Inc. PHAT | $442 million | n/a | n/a | -9.3% | 86.8% | n/a | n/a |
| Aquestive Therapeutics, Inc. AQST | $442 million | n/a | n/a | -114.1% | 12.5% | n/a | n/a |
| CytomX Therapeutics, Inc. CTMX | $434 million | n/a | -30.0% | -676.5% | -87.7% | 0.00 | n/a |
| Puma Biotechnology, Inc. PBYI | $420 million | 17.65 | 16.3% | 11.3% | 9.4% | 0.00 | n/a |
| CorMedix Inc. CRMD | $416 million | 2.50 | 40.6% | 47.0% | n/a | 0.00 | n/a |
| Crescent Biopharma, Inc. CBIO | $386 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Canopy Growth Corp. CGC | $251 million | n/a | n/a | -54.2% | 10.7% | 0.38 | n/a |
| Atrium Therapeutics, Inc. RNA | $141 million | n/a | n/a | n/a | n/a | n/a | n/a |
| Gossamer Bio, Inc. GOSS | $69 million | n/a | n/a | -140.0% | 78.0% | n/a | n/a |
124 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.